Medtronic PLC (MDT) delivered better-than-expected financial results for the second quarter of fiscal 2026. The company reported earnings per share (EPS) of $1.36, surpassing Wall Street's consensus estimate of $1.33 by $0.03. Revenue matched expectations at $9.0 billion.
The results reflect Medtronic's continued operational strength within the health care sector, where it specializes in the development and distribution of device-based medical therapies and services. The company’s diverse product offerings include advanced surgical technology, cardiac rhythm management, and spinal and orthopedic solutions.
Investors will have the opportunity to gain further insights during the upcoming earnings conference call, scheduled for before market open, where management will discuss these results and provide additional commentary on business performance.
As of November 13, 2025, Medtronic holds a market capitalization of $122.9 billion, with a price-to-earnings (P/E) ratio of 26.37 and a trailing twelve-month (TTM) EPS of 3.62. The company also boasts a substantial dividend yield of 296.4%. Looking ahead, analysts estimate EPS of $1.72 and revenue of $9.7 billion for the next earnings report on May 20, 2026.
This update provides insight into Medtronic PLC's recent operational performance and financial health, indicating stronger-than-anticipated business fundamentals. Investors are encouraged to review the full earnings release and management commentary for a comprehensive understanding of the quarter’s performance and future outlook.